Kornimate/medical-research-clean huggingface dataset:
lexical priming by music in alzheimer's disease and healthy aging

Conditions: Alzheimer Disease

Summary: while verbal memory is quickly reached in the wake of alzheimer's disease, the musical memory remains preserved until a late stage of the disease. this observation encouraged the development of music-based therapies in the management of neurocognitive and behavioral disorders that characterize alzheimer's disease. in order to develop rehabilitation programs that effectively target cognitive functions to stimulate, it is necessary to understand the mechanisms underlying this beneficial effect of music on cognition.

the investigators study the stimulation by the song, material integrating language and music, and having an autobiographical value. the investigators measure the lexical priming capacity of the song, that is, its ability to activate and maintain lexical and semantic representations, which are threatened with alteration in the course of the disease. this lexical priming effect by song is measured in patients with mild alzheimer's disease and healthy volunteers during a single test session. in the first phase of the session, participants are exposed to familiar songs, presented in sung, spoken or instrumental form, whose popularity they evaluate. in the second phase, they perform two implicit memory tasks: a trigram completion task and a lexical decision task. these tests measure the facilitation of the processing of words evoked by songs in relation to words unrelated to songs, reflecting a "long-term" memory update of mnemic traces of primed words.

Eligibility criteria:
inclusion criteria for patients : * presence of diagnostic criteria for alzheimer's disease * age ≥ 65 years * mmse (mini-mental state examination) ≥ 20 exclusion criteria for patient : * unstable clinical presentation or language presentation in the foreground * cognitive disorder of etiology different from that of alzheimer's disease inclusion criteria for volunteers : * age ≥ 18 years * absence of neurological or psychiatric antecedents * for those aged 65 or over: mmse (mini-mental state examination) greater than or equal to 27; non-pathological performance against the 5 words of dubois and the verbal fluency test. exclusion criteria for volunteers : * visual or auditory disorders insufficiently corrected * oral or written expression in french insufficient to carry out tests * consumption of psychotropic drugs not stabilized

Keywords: lexical priming healthy aging
the effect of local cold application on hypertension

Conditions: Hypertension

Summary: this study will be conducted to evaluate the effect of local cold application to the nape of the neck on systolic blood pressure, diastolic blood pressure, heart rate, heart rate pressure and headache.

aim: this study will be conducted to evaluate the effect of local cold application to the nape of the neck on systolic blood pressure, diastolic blood pressure, heart rate, heart rate pressure and headache. material and method: this study, which is planned as a randomized controlled and experimental study, will be conducted with type 2 (systolic blood pressure between 160 and 179 mmhg, diastolic blood pressure between 100 and 109 mmhg) essential hypertension patients who refer to van yüzüncü yıl university dursun odabaş medical centre emergency service. the patients will be distributed as 24 in experimental group, 24 in placebo group and 24 in control group based on block randomization (gender and age) method and a total of 72 patients will be included. patient information form, blood pressure and heart rate monitoring form and vas pain scale will be used to collect study data. patients in all groups will be measured in 90 minutes for a total of 8 times, as pre-test (pre-application) and post-test (minutes 3, 10, 15, 20, 30, 60 and 90). after routine medication therapy is given to all three groups, the cold gel pack which has been kept at least for four hours in the freezer will be applied to the nape of the patients in the experimental group, while gel pack at room temperature will be applied to the placebo group and no application will be made to the control group. variance analysis, friedman analysis, t test, wilcoxon test and kruskal wallis analysis will be used in data assessment.

Eligibility criteria:
inclusion criteria: * 25 mg sublingual ace inhibitor given as a treatment protocol, * no wound on the nape, * does not develop cold intolerance, * not taking any hypertension medication and pain medication in the last 6 hours, * without heart diseases, peripheral arterial circulation disorders, sensory disorders and edema, * not pregnant, * agreeing to participate in the study, * essential hypertension patients with systolic blood pressure 160 - 179 mmhg, diastolic blood pressure 100 - 109 mmhg. exclusion criteria: * developing cold intolerance, * changes in the treatment regimen, * panic attack, allergic reaction and any similar situation develops, * those who want to withdraw from the research

Keywords: cold application headache heart rate nursing
behavioral economics for oral health innovation trial

Conditions: Toothbrushing; Dental Plaque; Parent-Child Relations; Oral Hygiene; Dental Caries

Summary: this phase ii stratified randomized prevention trial will assess the efficacy of a behavioral economic theory-based financial incentive drawing program versus a control regimen to promote early childhood caries (ecc) preventive health behaviors (toothbrushing performance) for young children of predominantly latino parents/caregivers in early head start (ehs) and day care center programs.


Eligibility criteria:
inclusion criteria: * child * at least 2 fully erupted teeth * enrolled in, or waitlisted for, one of the participating los angeles county early head start (ehs) or affiliated day care center or area clinic programs * parent/caregiver * provide signed and dated informed consent form in english or spanish * agree to comply with all study procedures and be available for the duration of the study * aged 18 or older * speak either english or spanish and self-reported ability to read and write either english or spanish * be a parent or caregiver of a child at least 6 months old but less than 4 years (48 months), with at least 2 fully erupted teeth and enrolled in, or waitlisted for, one of the participating los angeles county ehs or affiliated day care center or area clinic programs * not be planning to move residence for the next 18 months outside the greater los angeles area * own a smartphone with google play or itunes store app and be willing to download and install the smart powered toothbrush app at the screening visit and keep it installed for the duration of the project. \[if the app cannot be properly installed by the baseline visit, the participant will not be randomized.\] * be willing to be contacted via text-messaging (sms) for study related notifications, such as incentives earned or reminders to sync the toothbrush * stakeholder * be a staff member at a participating study site (e.g. ehs or affiliated day care center) * verbally agree to participate after being provided a study information sheet exclusion criteria: * child * known allergic reaction to components of the study product(s) * uncooperative or behaviorally unsuited (assessed during a toothbrush prophylaxis, astdd basic screening survey caries screening, and photograph of maxillary incisors at the screening visit) * more than 2 crowns on maxillary incisor teeth (teeth# d, e, f, g, or equivalently #52, 51, 61, 62). * participated in the beecon pilot trial * a sibling of a child enrolled in the study (the family's oldest child in the eligible age range will be the study child) * enrolled in foster care * anything else that would place him/her at increased health risk or preclude the individual's full compliance with or completion of the study * parent/caregiver * participated in the beecon pilot trial * unable or unwilling to install and use the smart powered toothbrush app during the run-in period

Keywords: preventive dentistry health disparities health behavior behavioral economics
international gne myopathy patient registry

Conditions: GNE Myopathy; Hereditary Inclusion Body Myopathy

Summary: gne myopathy, an ultra-rare disease, is a severe progressive myopathy that typically presents in early adulthood as weakness in the distal muscles of the lower extremities and progresses proximally, leading to a loss of muscle strength and function, and ultimately a wheelchair-bound state. the rate of progression is gradual and variable over the course of 10-20 years or longer. there is a need to understand the world wide epidemiology of this ultra-rare condition, better understand a long-term disease course and the progression of disease-specific features, support translational research by evaluating burden illness and support clinical research recruitment. therefore, the study will longitudinally collect information via an online patient registry platform.

gne myopathy is an ultra- rare condition. most of the knowledge is coming from case reports or small cohort observations. there is a need to more precisely understand the long-term disease course and the progression of disease-specific features of gne myopathy, and in turn characterise the overall burden of this illness. also, to better understand the disease, describe it variability, genotype-phenotype correlation, quality of life, epidemiology, health-economics aspects and need for assistive walking devices. collected data needs to be harmonised to be compatible collaborative work with remudy (japanese patient registry). this collaborative effort will enable the analysis of the largest gne myopathy data set in the world. to this end, this study will collect patient information longitudinally. upon patient's agreement, the registry curator can contact nominated clinicians to request additional data or data validation. study objectives the objectives of the study are to: * longitudinally characterize disease-specific features of gne myopathy * characterize the burden of illness and quality of life in patients with gne myopathy * support recruitment in research activities * inform registry participants via newsletters about scientific developments in the gne myopathy field

Eligibility criteria:
inclusion criteria: * aged 18 years or older at the time of informed consent * clinical and/or genetic diagnosis of gne myopathy (also known as hibm, qsm, inclusion body myopathy type 2, dmrv, or nonaka disease) * willing and able to provided electronic (or written) consent and comply with all study requirements. exclusion criteria: * under 18 years of age

Keywords: distal myopathies neuromuscular diseases muscular dystrophies gne myopathy hereditary inclusion body myopathy
a multicenter randomized open-label study of oseltamivir combined with hd-dex versus hd-dex in the management of itp

Conditions: Thrombocytopenia

Summary: oseltamivirphosphate is hydrolysed to its active metabolite-the free carboxylate of oseltamivir. oseltamivir is a neuraminidase inhibitor, serving as a competitive inhibitor of the activity of the viral neuraminidase (na) enzyme upon sialic acid, found on glycoproteins on the surface of platelets. by blocking the activity of the enzyme, oseltamivir may prevent platelet destruction in liver.the project was undertaking by qilu hospital of shandong university and other 4 well-known hospitals in china. in order to report the efficacy and safety of oseltamivirphosphate combined with high-dose dexamethasone for the treatment of immune thrombocytopenia (itp) with high platelet desialylation level, compared to high-dose dexamethasone therapy.

the investigators are undertaking a parallel group, multicentre, randomised controlled trial of 50 newly diagnosed itp adult patients with high platelet desialylation level from 5 medical centers in china. one part of the participants are randomly selected to receiver hd-dxm (orally at 40 mg daily for 4d) combined with oseltamivir (orally at 75 mg twice for 10d), the others are selected to receive hd-dxm (orally at 40 mg daily for 4d ) alone. if platelet counts remained \<30×109/l or there were bleeding symptoms by day 10, another 4-day course of hd-dxm was given (days 10-14).for the combination arm, patients with an initial response relapsed during the follow-up period, oseltamivir retreatment could be given for another 10 days at the discretion of the physician's advice and patients' will. platelet count, bleeding , platelet desialylation level and other symptoms were evaluated before and after treatment. adverse events are also recorded throughout the study. in order to report the efficacy and safety of oseltamivirphosphate combining with high-dose dexamethasone therapy compared to high-dose dexamethasone for the treatment of adults with newly diagnosed itp .

Eligibility criteria:
inclusion criteria: * newly diagnosed itp patients need of treatment(s) to minimize the risk of clinically significant bleeding primary itp confirmed by excluding other supervened causes of thrombocytopenia exclusion criteria: * pregnancy hypertension cardiovascular disease diabetes liver and kidney function impairment hcv, hiv, hbsag seropositive status patients with systemic lupus erythematosus and/or antiphospholipid syndrome

Keywords: oseltamivir dexamethasone itp
coronavirus induced acute respiratory disease syndrome during pregnancy

Conditions: Acute Respiratory Distress Syndrome Related to SARS-CoV-2

Summary: few data are available on the management of critically ill pregnant women with pneumonia related to sars-cov-2. in the absence of clear recommendations for the management of delivery, clinicians are faced with the risk of pregnancy continuation against the risk of premature birth. in these multicenter retrospective study, the investigators want to describe clinicians attitude on delivery management in pregnant women requiring invasive mechanical ventilation for acute respiratory distress syndrome related to sars-cov-2. two strategies will be compared on maternal, obstetric and neonatal outcomes: * wait strategy defined by no extraction within 24 hours of invasive venting * early strategy defined by extraction within 24 hours of invasive ventin


Eligibility criteria:
1. patient \> 18 years 2. patient with sars-cov-2 pneumonia proven by rt-pcr 3. hospitalization in an intensive care unit during pregnancy after 14 weeks' gestation 4. need for ventilatory support including: oxygen therapy \> 6l/min and/or niv and/or high flow oxygen and/or invasive mechanical ventilation +/- ecmo. exclusion criteria: * patient's refusal to participate in this study

Keywords: covid-19, acute respiratory distress syndrome pregnancy preterm delivery sars-cov-2 icu critical care mechanical ventilation
a study of the effect of probiotics on gastrointestinal function during pregnancy

Conditions: Pregnancy Early; Nausea Gravidarum; Vomiting of Pregnancy

Summary: the purpose as well as the aim of this project is to understand the effect of probiotics on gastrointestinal (gi) dysfunction such as nausea, vomiting, and constipation that are found during the first and second trimesters of pregnancy. the primary objective of this project is to uncover whether probiotics have an effect on gi functional disorders. the secondary objective is to identify the microbiota associated with probiotic intake. the tested hypothesis is that gut microbiota influences the gi functions and may influence constipation, nausea, and vomiting during pregnancy.


Eligibility criteria:
inclusion criteria: * first and second trimester healthy or low risk pregnant women who report gastrointestinal disorders such as nausea, vomiting, and constipation definition of healthy or low risk pregnant women: * systolic blood pressure \< 140 mmhg and diastolic blood pressure \< 90 mmhg * hemoglobin ≥ 10.0 g/dl * have immunity against rubella (german measles) * hiv negative * urine test shows no sign of kidney or urinary tract infection * 27 weeks 6 days gestation or less with confirmed fetal heart beat * pregnant women age 18 and older exclusion criteria: * high risk pregnant women who have existing health conditions such as high blood pressure, type 1 diabetes, hiv positive, or are infected with hepatitis b, syphilis, or other sexually transmitted diseases * pregnant women who have multiple gestations or a history of recurrent miscarriages (more than two consecutive miscarriages) * had prior bariatric surgery * conceived through ivf program * pregnant women who have had severe weight loss (more than 5 pounds) during pregnancy. \[note: mild weight loss (2-3 pounds) due to nausea, vomiting, or loss of appetite is considered normal.\] * medical history of irritable bowel syndrome or other non-pregnancy related gi dysfunction/disorder
a randomized phase iii study of palliative radiation of advanced central tumors with intentional avoidance of the esophagus

Conditions: Non-Small Cell Lung Cancer

Summary: a randomized phase ii study of palliative radiation of advanced central lung tumors with intentional avoidance of the esophagus. patients will be randomized between standard of care palliative thoracic radiation and esophageal-sparing intensity-modulated radiation therapy (es-imrt) in a 1:1 ratio. radiotherapy will be administered as soon as possible following randomization and subjects will be followed for 1 year after completion of their radiation therapy. the primary endpoint is esophageal quality of life as measured by the esophageal cancer subscore (ecs) of the functional assessment of cancer therapy-esophagus (fact-e).


Eligibility criteria:
inclusion criteria: * american joint committee on cancer (ajcc) 7th edition stage iv nsclc or stage iii not eligible for curative intent treatment * intended to receive palliative radiotherapy to the thorax, to a dose of 30gy in 10 fractions or 20gy in 5 fractions. in either treatment arm at least 5cm of the esophagus should be in the intended treatment field. * willingness and ability to provide informed consent * eastern cooperative oncology group (ecog) performance status 0-3 * age 18 years or older * prior or planned systemic therapy (chemotherapy, immunotherapy, targeted agents) is permissible at the discretion of the treating medical oncologist, provided that no systemic treatment is given within 2 weeks prior to rt, concurrent with rt or within a 2-week period post rt. * concurrent palliative rt to other metastatic sites is permissible * life expectancy \> 3 months exclusion criteria: * prior thoracic rt * serious medical comorbidities precluding rt * pregnant or lactating women * inability to attend the full course of rt or planned follow-up visits * planned concurrent palliative rt to the stomach and/or liver * congenital abnormalities of the esophagus or severe disorders of the esophagus (e.g. achalasia)

Keywords: esophageal sparing conventional radiotherapy palliative radiation central lung tumors
fish oil trials in pregnancy for the prevention of pregnancy complications ('fotip')

Conditions: Preterm Birth; Intrauterine Growth Retardation; Pregnancy Induced Hypertension

Summary: the initial trial examined if fish oil supplementation during pregnancy could reduce the risk of pregnancy induced hypertension, intrauterine growth retardation, and preterm birth in pregnancies that were at increased risk of these complications. the study was designed as a multi-centre clinical trial based in 19 hospitals in seven countries in europe.


Eligibility criteria:
inclusion criteria: * there were six subgroups with different inclusion criteria: * the low dose (prophylactic) section enrolled women who after 16 weeks of gestation had been identified with an uncomplicated pregnancy, who in an earlier pregnancy had experienced preterm delivery (this was subgroup 1) * intrauterine growth retardation (subgroup 2) or pregnancy induced hypertension (subgroup 3) * women who had been identified with twin pregnancies (subgroup 4) * the high dose ('therapeutic') section enrolled women with threatening pre-eclampsia (subgroup 5) or suspected intrauterine growth retardation in the current pregnancy (subgroup 6). exclusion criteria: * diabetes mellitus in or before pregnancy * diagnosed severe fetal malformation or hydrops in current pregnancy * suspicion in current pregnancy, or occurrence in an earlier pregnancy, of placental abruption * drug or alcohol abuse * regular intake of fish oil or of non-steroidal antiinflammatory agents or other drugs with an effect on thombocyte function or eicosanoid metabolism * allergy to fish products.

Keywords: fish oil supplementation rct high risk pregnancies twin pregnancy preterm birth intrauterine growth retardation pregnancy induced hypertension
the impact of sepsis on long-term outcomes in critical ill children with sepsis

Conditions: Sepsis; Children, Only

Summary: this study is conducted in critically ill children with sepsis with a five years follow-up. we aim to investigate the impact of sepsis on long-term outcomes including growth, neurodevelopment, survival rate, quality of life.


Eligibility criteria:
inclusion criteria: we included critically ill children with sepsis who successfully discharged from pediatric intensive care units, age \< 16 years. we also included age, sex, illness severity matched critically ill children as control group. exclusion criteria: we excluded children with underlying diseases, cancer, hematologic malignancy.
aplidin - dexamethasone in relapsed/refractory myeloma

Conditions: Relapsed/Refractory Multiple Myeloma

Summary: study of plitidepsin in combination with dexamethasone versus dexamethasone alone in patients with relapsed/refractory multiple myeloma.

phase iii study in patients with relapsed/refractory multiple myeloma to compare the efficacy of plitidepsin in combination with dexamethasone vs. dexamethasone alone measured by progression-free survival (pfs) and to evaluate tumor response, duration of response (dr), overall survival (os) and to rule out any effect of plitidepsin on the duration of the qt/qtc interval (time corresponding to the beginning of depolarization to re-polarization of the ventricles).

Eligibility criteria:
inclusion criteria: * age ≥ 18 years. * eastern cooperative oncology group (ecog) performance status (ps) ≤ 2 * life expectancy ≥ 3 months. * patients previously diagnosed with multiple myeloma * patients must have relapsed or relapsed and refractory multiple myeloma (mm) after at least three but not more than six prior therapeutic regimens for mm, including induction therapy and stem cell transplant in candidate patients, which will be considered as only one regimen. * patients must have received previous bortezomib-containing and lenalidomide-containing regimens (or thalidomide where lenalidomide is not available) * women must have a negative serum pregnancy test * voluntarily signed and dated written informed consent exclusion criteria: * concomitant diseases/conditions * women who are pregnant or breast feeding. * concomitant medications that include corticosteroids, chemotherapy, or other therapy that is or may be active against mm * known hypersensitivity to any involved study drug or any of its formulation components

Keywords: multiple myeloma aplidin plitidepsin dexamethasone